Cyclin genes as potential novel prognostic biomarkers and therapeutic targets in breast cancer
- Authors:
- Nian-Qiu Liu
- Wei-Han Cao
- Xing Wang
- Junyao Chen
- Jianyun Nie
-
Affiliations: Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Center, Kunming, Yunnan 650000, P.R. China, Department of Ultrasound, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650000, P.R. China - Published online on: September 5, 2022 https://doi.org/10.3892/ol.2022.13494
- Article Number: 374
-
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
 |
 |
|
Cai Z and Liu Q: Cell cycle regulation in treatment of breast cancer. Adv Exp Med Biol. 1026:251–270. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Steeg PS and Zhou Q: Cyclins and breast cancer. Breast Cancer Res Treat. 52:17–28. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Bai C, Richman R and Elledge SJ: Human cyclin F. EMBO J. 13:6087–6098. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Ye C, Wang J, Wu P, Li X and Chai Y: Prognostic role of cyclin B1 in solid tumors: A meta-analysis. Oncotarget. 8:2224–2232. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lee YS, Ryu SW, Bae SJ, Park TH, Kwon K, Noh YH and Kim SY: Cross-platform meta-analysis of multiple gene expression profiles identifies novel expression signatures in acquired anthracycline-resistant breast cancer. Oncol Rep. 33:1985–1993. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Miftakhova R, Hedblom A, Semenas J, Robinson B, Simoulis A, Malm J, Rizvanov A, Heery DM, Mongan NP, Maitland NJ, et al: Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow. Cancer Res. 76:2453–2464. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li R, Jiang X, Zhang Y, Wang S, Chen X, Yu X, Ma J and Huang X: Cyclin B2 overexpression in human hepatocellular carcinoma is associated with poor prognosis. Arch Med Res. 50:10–17. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Dorn J, Spatz H, Schmieder M, Barth TF, Blatz A, Henne-Bruns D, Knippschild U and Kramer K: Cyclin H expression is increased in GIST with very-high risk of malignancy. BMC Cancer. 10:3502010. View Article : Google Scholar : PubMed/NCBI | |
|
Huang KC, Yang J, Ng MC, Ng SK, Welch WR, Muto MG, Berkowitz RS and Ng SW: Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells. Eur J Cancer. 67:152–163. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chujan S, Kitkumthorn N, Siriangkul S and Mutirangura A: CCNA1 promoter methylation: A potential marker for grading Papanicolaou smear cervical squamous intraepithelial lesions. Asian Pac J Cancer Prev. 15:7971–7975. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Takashima S, Saito H, Takahashi N, Imai K, Kudo S, Atari M, Saito Y, Motoyama S and Minamiya Y: Strong expression of cyclin B2 mRNA correlates with a poor prognosis in patients with non-small cell lung cancer. Tumour Biol. 35:4257–4265. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wiseman M: The second world cancer research fund/American institute for cancer research expert report. Food, nutrition, physical activity, and the prevention of cancer: A global perspective. Proc Nutr Soc. 67:253–256. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Harbeck N and Gnant M: Breast cancer. Lancet. 389:1134–1150. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng X, Liu C, Yao J, Wan H, Wan G, Li Y and Chen N: Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications. Pharmacol Res. 163:1053202021. View Article : Google Scholar : PubMed/NCBI | |
|
Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH, et al: Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood. 119:5492–5501. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yang R, Nakamaki T, Lübbert M, Said J, Sakashita A, Freyaldenhoven BS, Spira S, Huynh V, Müller C and Koeffler HP: Cyclin A1 expression in leukemia and normal hematopoietic cells. Blood. 93:2067–2074. 1999.PubMed/NCBI | |
|
Gao T, Han Y, Yu L, Ao S, Li Z and Ji J: CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance. PLoS One. 9:e917712014. View Article : Google Scholar : PubMed/NCBI | |
|
Hein JB and Nilsson J: Interphase APC/C-Cdc20 inhibition by cyclin A2-Cdk2 ensures efficient mitotic entry. Nat Commun. 7:109752016. View Article : Google Scholar : PubMed/NCBI | |
|
Pei J, Zhang J, Yang X, Wu Z, Sun C, Wang Z and Wang B: NEK5 promotes breast cancer cell proliferation through up-regulation of cyclin A2. Mol Carcinog. 58:933–943. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ding K, Li W, Zou Z, Zou X and Wang C: CCNB1 is a prognostic biomarker for ER+ breast cancer. Med Hypotheses. 83:359–564. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu HY, Liu YY, Yang F, Zhang L, Zhang FL, Hu X, Shao ZM and Li DQ: Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer. Nucleic Acids Res. 48:3638–3656. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yu AQ, Wang ZX, Wu W, Chen KY, Yan SR and Mao ZB: Circular RNA CircCCNB1 sponges micro RNA-449a to inhibit cellular senescence by targeting CCNE2. Aging (Albany NY). 11:10220–10241. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shubbar E, Kovács A, Hajizadeh S, Parris TZ, Nemes S, Gunnarsdóttir K, Einbeigi Z, Karlsson P and Helou K: Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. BMC Cancer. 13:12013. View Article : Google Scholar : PubMed/NCBI | |
|
Qian X, Song X, He Y, Yang Z, Sun T, Wang J, Zhu G, Xing W and You C: CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients. Biomed Pharmacother. 74:222–227. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gao Z, Man X, Li Z, Bi J, Liu X, Li Z, Zhu Y, Zhang Z and Kong C: Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma. Oncol Rep. 41:2440–2452. 2019.PubMed/NCBI | |
|
Lozano JC, Perret E, Schatt P, Arnould C, Peaucellier G and Picard A: Molecular cloning, gene localization, and structure of human cyclin B3. Biochem Biophys Res Commun. 291:406–413. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Han H, Bertrand KC, Patel KR, Fisher KE, Roy A, Muscal JA and Venkatramani R: BCOR-CCNB3 fusion-positive clear cell sarcoma of the kidney. Pediatr Blood Cancer. 67:e281512020. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshida A, Arai Y, Hama N, Chikuta H, Bando Y, Nakano S, Kobayashi E, Shibahara J, Fukuhara H, Komiyama M, et al: Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults. Histopathology. 76:509–520. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shibayama T, Okamoto T, Nakashima Y, Kato T, Sakurai T, Minamiguchi S, Kataoka TR, Shibuya S, Yoshizawa A, Toguchida J and Haga H: Screening of BCOR-CCNB3 sarcoma using immunohistochemistry for CCNB3: A clinicopathological report of three pediatric cases. Pathol Int. 65:410–414. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ren S and Rollins BJ: Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell. 117:239–251. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Miyata Y, Liu Y, Jankovic V, Sashida G, Lee JM, Shieh JH, Naoe T, Moore M and Nimer SD: Cyclin C regulates human hematopoietic stem/progenitor cell quiescence. Stem Cells. 28:308–317. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Xu W and Ji JY: Dysregulation of CDK8 and cyclin C in tumorigenesis. J Genet Genomics. 38:439–452. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yu YN, Yip GW, Tan PH, Thike AA, Matsumoto K, Tsujimoto M and Bay BH: Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle. Int J Oncol. 37:483–492. 2010.PubMed/NCBI | |
|
Roy PG and Thompson AM: Cyclin D1 and breast cancer. Breast. 15:718–127. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Elsheikh S, Green AR, Aleskandarany MA, Grainge M, Paish CE, Lambros MB, Reis-Filho JS and Ellis IO: CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat. 109:325–335. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
He Q, Wu J, Liu XL, Ma YH, Wu XT, Wang WY and An HX: Clinicopathological and prognostic significance of cyclin D1 amplification in patients with breast cancer: A meta-analysis. J BUON. 22:1209–1216. 2017.PubMed/NCBI | |
|
Villegas SL, Darb-Esfahani S, von Minckwitz G, Huober J, Weber K, Marmé F, Furlanetto J, Schem C, Pfitzner BM, Lederer B, et al: Expression of cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 168:179–187. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Q, Li Y, Li S, Jin L, Lai H, Wu Y, Cai Z, Zhu M, Li Q, Li Y, et al: LncRNA DILA1 inhibits cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer. Nat Commun. 11:55132020. View Article : Google Scholar : PubMed/NCBI | |
|
Pors J, Naso J, Berg K and Churg A: Cyclin D1 immunohistochemical staining to separate benign from malignant mesothelial proliferations. Mod Pathol. 33:312–318. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kwapisz D: Cyclin-dependent kinase 4/6 inhibitors in breast cancer: Palbociclib, ribociclib, and abemaciclib. Breast Cancer Res Treat. 166:41–54. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hung CS, Wang SC, Yen YT, Lee TH, Wen WC and Lin RK: Hypermethylation of CCND2 in lung and breast cancer is a potential biomarker and drug target. Int J Mol Sci. 19:30962018. View Article : Google Scholar : PubMed/NCBI | |
|
Callahan CL, Wang Y, Marian C, Weng DY, Eng KH, Tao MH, Ambrosone CB, Nie J, Trevisan M, Smiraglia D, et al: DNA methylation and breast tumor clinicopathological features: The western New York exposures and breast cancer (WEB) study. Epigenetics. 11:643–652. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ding ZY, Li R, Zhang QJ, Wang Y, Jiang Y, Meng QY, Xi QL and Wu GH: Prognostic role of cyclin D2/D3 in multiple human malignant neoplasms: A systematic review and meta-analysis. Cancer Med. 8:2717–2729. 2019.PubMed/NCBI | |
|
Luhtala S, Staff S, Tanner M and Isola J: Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer. Tumour Biol. 37:9813–9823. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, et al: Cyclin E and survival in patients with breast cancer. N Engl J Med. 347:1566–1575. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Lee C, Fernandez KJ, Alexandrou S, Sergio CM, Deng N, Rogers S, Burgess A and Caldon CE: Cyclin E2 promotes whole genome doubling in breast cancer. Cancers (Basel). 12:22682020. View Article : Google Scholar : PubMed/NCBI | |
|
Peek GW and Tollefsbol TO: Combinatorial PX-866 and raloxifene decrease Rb phosphorylation, cyclin E2 transcription, and proliferation of MCF-7 breast cancer cells. J Cell Biochem. 117:1688–1696. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lindskog C: The potential clinical impact of the tissue-based map of the human proteome. Expert Rev Proteomics. 12:213–215. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fu J, Qiu H, Cai M, Pan Y, Cao Y, Liu L, Yun J and Zhang CZ: Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis. Cancer Sci. 104:508–515. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao L, Jiang L, He L, Wei Q, Bi J, Wang Y, Yu L, He M, Zhao L and Wei M: Identification of a novel cell cycle-related gene signature predicting survival in patients with gastric cancer. J Cell Physiol. 234:6350–6360. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Noh JM, Kim J, Cho DY, Choi DH, Park W and Huh SJ: Exome sequencing in a breast cancer family without BRCA mutation. Radiat Oncol J. 33:149–154. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tamura K, Kanaoka Y, Jinno S, Nagata A, Ogiso Y, Shimizu K, Hayakawa T, Nojima H and Okayama H: Cyclin G: A new mammalian cyclin with homology to fission yeast Cig1. Oncogene. 8:2113–2118. 1993.PubMed/NCBI | |
|
Zimmermann M, Arachchige-Don AP, Donaldson MS, Patriarchi T and Horne MC: Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival. Cell Cycle. 15:3278–3295. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wu D, Han B, Guo L and Fan Z: Molecular mechanisms associated with breast cancer based on integrated gene expression profiling by bioinformatics analysis. J Obstet Gynaecol. 36:615–621. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Knowles LM and Smith JW: Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer. BMC Genomics. 8:1682007. View Article : Google Scholar : PubMed/NCBI | |
|
Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET and Bergh J: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 102:13550–13555. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Mao L, Ling X and Chen J: Cyclin H regulates lung cancer progression as a carcinoma inducer. Comput Math Methods Med. 2021:66460772021. View Article : Google Scholar : PubMed/NCBI | |
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM: ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45((W1)): W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Nagy Á, Munkácsy G and Győrffy B: Pancancer survival analysis of cancer hallmark genes. Sci Rep. 11:60472021. View Article : Google Scholar : PubMed/NCBI | |
|
Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, et al: Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 173:291–304.e6. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
R Core Team: R: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna: 2012 | |
|
RStudio Team, . RStudio: Integrated Development for R. RStudio Inc. Boston, MA: 2015 | |
|
Tang T, Guo C, Xia T, Zhang R, Zen K, Pan Y and Jin L: LncCCAT1 promotes breast cancer stem cell function through activating WNT/β-catenin signaling. Theranostics. 9:7384–7402. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shao F, Pang X and Baeg GH: Targeting the JAK/STAT signaling pathway for breast cancer. Curr Med Chem. 28:5137–5151. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Costa RLB, Han HS and Gradishar WJ: Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: A review. Breast Cancer Res Treat. 169:397–406. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Zeng Z, Wang J, Wu Y, Chen W, Zheng L, Xi T, Wang A and Lu Y: MicroRNA-9 and breast cancer. Biomed Pharmacother. 122:1096872020. View Article : Google Scholar : PubMed/NCBI | |
|
Qiao K, Ning S, Wan L, Wu H, Wang Q, Zhang X, Xu S and Pang D: LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway. J Exp Clin Cancer Res. 38:4182019. View Article : Google Scholar : PubMed/NCBI | |
|
Lee MG, Kwon YS, Nam KS, Kim SY, Hwang IH, Kim S and Jang H: Chaga mushroom extract induces autophagy via the AMPK-mTOR signaling pathway in breast cancer cells. J Ethnopharmacol. 274:1140812021. View Article : Google Scholar : PubMed/NCBI | |
|
Woo SH, Seo SK, An S, Choe TB, Hong SI, Lee YH and Park IC: Implications of caspase-dependent proteolytic cleavage of cyclin A1 in DNA damage-induced cell death. Biochem Biophys Res Commun. 453:438–442. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Klajic J, Busato F, Edvardsen H, Touleimat N, Fleischer T, Bukholm I, Børresen-Dale AL, Lønning PE, Tost J and Kristensen VN: DNA methylation status of key cell-cycle regulators such as CDKNA2/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors. Clin Cancer Res. 20:6357–6366. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Deng JL, Xu YH and Wang G: Identification of potential crucial genes and key pathways in breast cancer using bioinformatic analysis. Front Genet. 10:6952019. View Article : Google Scholar : PubMed/NCBI | |
|
Tang J, Kong D, Cui Q, Wang K, Zhang D, Gong Y and Wu G: Prognostic genes of breast cancer identified by gene co-expression network analysis. Front Oncol. 8:3742018. View Article : Google Scholar : PubMed/NCBI | |
|
Jayanthi VSPKSA, Das AB and Saxena U: Grade-specific diagnostic and prognostic biomarkers in breast cancer. Genomics. 112:388–396. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou H, Lv Q and Guo Z: Transcriptomic signature predicts the distant relapse in patients with ER+ breast cancer treated with tamoxifen for five years. Mol Med Rep. 17:3152–3157. 2018.PubMed/NCBI | |
|
Li N, Fassl A, Chick J, Inuzuka H, Li X, Mansour MR, Liu L, Wang H, King B, Shaik S, et al: Cyclin C is a haploinsufficient tumour suppressor. Nat Cell Biol. 16:1080–1091. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bozickovic O, Hoang T, Fenne IS, Helland T, Skartveit L, Ouchida M, Mellgren G and Sagen JV: Cyclin C interacts with steroid receptor coactivator 2 and upregulates cell cycle genes in MCF-7 cells. Biochim Biophys Acta. 1853:2383–2391. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S and Sonoo H: Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin Cancer Res. 6:512–518. 2000.PubMed/NCBI | |
|
Butt AJ, McNeil CM, Musgrove EA and Sutherland RL: Downstream targets of growth factor and oestrogen signalling and endocrine resistance: The potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer. 12 (Suppl 1):S47–S59. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, et al: Association of p27 and cyclin D1 expression and benefit from adjuvant trastuzumab treatment in HER2-positive early breast cancer: A TransHERA study. Clin Cancer Res. 24:3079–3086. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tobin NP, Sims AH, Lundgren KL, Lehn S and Landberg G: Cyclin D1, Id1 and EMT in breast cancer. BMC Cancer. 11:4172011. View Article : Google Scholar : PubMed/NCBI | |
|
Fischer H, Chen J, Skoog L and Lindblom A: Cyclin D2 expression in familial and sporadic breast cancer. Oncol Rep. 9:1157–1161. 2002.PubMed/NCBI | |
|
Li Z, Heng J, Yan J, Guo X, Tang L, Chen M, Peng L, Wu Y, Wang S, Xiao Z, et al: Integrated analysis of gene expression and methylation profiles of 48 candidate genes in breast cancer patients. Breast Cancer Res Treat. 160:371–383. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Justenhoven C, Pierl CB, Haas S, Fischer HP, Hamann U, Baisch C, Harth V, Spickenheuer A, Rabstein S, Vollmert C, et al: Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors. Int J Cancer. 124:2077–2081. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, DeMichele A, Harbeck N, André F, Bayar MA, et al: Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. J Clin Oncol. 37:1169–1178. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao ZM, Yost SE, Hutchinson KE, Li SM, Yuan YC, Noorbakhsh J, Liu Z, Warden C, Johnson RM, Wu X, et al: CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer. BMC Cancer. 19:962019. View Article : Google Scholar : PubMed/NCBI | |
|
Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, et al: Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res. 12:3319–3328. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Seyhan AA, Varadarajan U, Choe S, Liu W and Ryan TE: A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers. Mol Biosyst. 8:1553–1570. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gupta ED, Pachauri M, Ghosh PC and Rajam MV: Targeting polyamine biosynthetic pathway through RNAi causes the abrogation of MCF 7 breast cancer cell line. Tumour Biol. 37:1159–1171. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Zhang T, Zhang S and Shan J: Prognostic values of F-box members in breast cancer: An online database analysis and literature review. Biosci Rep. 39:BSR201809492019. View Article : Google Scholar : PubMed/NCBI | |
|
Piscopo DM and Hinds PW: A role for the cyclin box in the ubiquitin-mediated degradation of cyclin G1. Cancer Res. 68:5581–5590. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Liu F, Gao X, Yu H, Yuan D, Zhang J, He Y and Yue L: Effects of expression of exogenous cyclin G1 on proliferation of human endometrial carcinoma cells. Chin J Physiol. 56:83–89. 2013.PubMed/NCBI | |
|
Tian JM, Ran B, Zhang CL, Yan DM and Li XH: Estrogen and progesterone promote breast cancer cell proliferation by inducing cyclin G1 expression. Braz J Med Biol Res. 51:1–7. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shahi RB, De Brakeleer S, Caljon B, Pauwels I, Bonduelle M, Joris S, Fontaine C, Vanhoeij M, Van Dooren S, Teugels E and De Grève J: Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families. BMC Cancer. 19:3132019. View Article : Google Scholar : PubMed/NCBI | |
|
Patel H, Abduljabbar R, Lai CF, Periyasamy M, Harrod A, Gemma C, Steel JH, Patel N, Busonero C, Jerjees D, et al: Expression of CDK7, cyclin H, and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor-positive breast cancer. Clin Cancer Res. 22:5929–5938. 2016. View Article : Google Scholar : PubMed/NCBI |
